Status:
RECRUITING
Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer
Lead Sponsor:
Institut Claudius Regaud
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a real-life situation, adherence to tamoxifen treatment as a function of the taking of alternative and compleme...
Eligibility Criteria
Inclusion
- Age ≥ 18 years at entry into the study.
- Patient treated for hormone-dependent localized breast cancer requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
- Patients treated with tamoxifen for a maximum of 1 to 3 years.
- Patient affiliated with a Social Security system in France.
- Patients who signed informed consent prior to inclusion in the study and prior to any specific study procedures.
Exclusion
- Pregnant or breastfeeding women.
- Any psychological, family, geographical or sociological condition that does not allow the medical follow-up and/or the procedures foreseen in the study protocol to be respected.
- Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
Key Trial Info
Start Date :
February 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04740697
Start Date
February 12 2021
End Date
February 1 2026
Last Update
April 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France, 31059